Tarceva boosts progression-free survival Cancerfacts.com, WA - Nov 12, 2008 Tarceva is also approved in combination with gemcitabine for the treatment of patients who have not received previous chemotherapy for locally advanced ...DNA - OSIP
Recent News and Articles on the Keywords: tarceva + fda + 0.20 Related to the article below (Last Update: 8/7/2008)
Allos Therapeutics Reports 2008 Second Quarter Results MarketWatch - Aug 5, 2008 The Company advanced patient enrollment in the Phase 2b, randomized, multi-center study comparing PDX and Tarceva(R) (erlotinib) in patients with Stage ...ALTH
Genentech's Q2 2008 earnings transcript BloggingStocks - Jul 14, 2008 We also look forward to the results of the beta lung study investigating a combination of Tarceva and Avastin without chemotherapy. ...DNA
Genentech Announces Second Quarter 2008 Results WELT ONLINE, Germany - Jul 14, 2008 These studies included two combination Phase III studies for Avastin? (bevacizumab) and Tarceva? (erlotinib) in first-line and second-line metastatic ...DNA
SuperGen Reports 2008 Second Quarter Financial Results MSN Money - Aug 4, 2008 ... of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) of a second drug emanating from the acquired technology. ...SUPG
OSI Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript Seeking Alpha, NY - Jul 23, 2008 Total revenues rose to $96 million, an increase of 21%, driven by a 32% increase in Tarceva related revenues, offset by lower levels of revenue related to ...OSIP
Exelixis Inc. Q2 2008 Earnings Call Transcript Seeking Alpha, NY - Aug 5, 2008 We reached agreement with the FDA on this phase 3 registration trial, via the special protocol assessment process, and I have also discussed the trial ...EXEL
S IGNAL T RANSDUCTION-D IRECTED C ANCER T REATMENTS* - EA Sausville, Y Elsayed, M Monga, G Kim - Annual Reviews in Pharmacology and Toxicology, 2003 - Annual Reviews ... OSI-774 (Erlotinib, Tarceva?) ... Sirolimus was approved by the FDA for prevention of
allograft rejection after ... extensive activity with a mean IC 50 of 0.20 ?M. ...
The Acyl Sulfonamide Antiproliferatives and Other Novel Antitumor Agents MM Mader - ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 2006 - books.google.com ... inhibitors such as sorafenib, and earlier, erlotinib (Tarceva? for non ... chemical entities
approved by the US FDA for oncology ... 14 6.3 5.9 13 18 0.20 0.30 0.36 ...
Antiangiogenic Therapy and Ovarian Cancer RT Penson, JA Rauh-Hain, NS Horowitz - 2008 - ingentaconnect.com ... differences in overall survival between groups (P>0.20). ... The US FDA approved sorafenib
as the first ... the efficacy and safety of erlotinib (Tarceva?, OSI-774 ... -
[CITATION] Guidelines and Recommendations for Laboratory Analysis and Application of Pharmacogenetics to … V Chairs -
Multimodality imaging of the HER-kinase axis in cancer - W Cai, G Niu, X Chen - European Journal of Nuclear Medicine and Molecular Imaging, 2008 - Springer ... a small-molecule inhibitor of EGFR, was the first drug of its class to gain FDA
approval for use in patients with NSCLC [54]. Erlotinib (Tarceva; OSI-774 ...
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases - O Fedorov, B Marsden, V Pogacic, P Rellos, S … - Proceedings of the National Academy of Sciences, 2007 - National Acad Sciences ... Food and Drug Administration (FDA)-approved drugs or ... Gleevec, Tarceva, and Iressa
were purchased from Biaffin ... nl of a solution containing 20% PEG 1K, 0.20 M Li ...
Source: Google Scholar
FDA has approved Tarceva in combination with Gemcitabine for advanced, inoperable or metastatic pancreatic cancer
The FDA ( U.S. Food and Drug Administration ) has approved Tarceva ( Erlotinib ) in combination with Gemcitabine chemotherapy for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy.
Tarceva is the first drug in a Phase III trial to have shown a significant improvement in overall survival when added to Gemcitabine chemotherapy as initial treatment for pancreatic cancer.
Tarceva is a once-daily oral tablet already approved for use in patients with non-small cell lung cancer ( NSCLC ) whose disease has progressed after one or more courses of chemotherapy.
Pancreatic cancer has the highest one-year mortality rate of any cancer. The average life expectancy for a patient diagnosed with metastatic pancreatic cancer is three to six months, according to The Pancreatic Cancer Action Network ( PanCAN ).
The FDA based its approval decision for Tarceva on results from a randomized double-blind, placebo-controlled Phase III clinical study of Tarceva, in combination with Gemcitabine chemotherapy in patients with unresectable locally advanced or metastatic pancreatic cancer.
The study met its primary endpoint of improving overall survival.
Compared to Gemcitabine plus placebo, those patients receiving Gemcitabine plus Tarceva 100 mg/day demonstrated a statistically significant ( 23 percent ) improvement in overall survival ( hazard ratio = 0.81; p = 0.028 ).
After one year, 24 percent of patients receiving Tarceva plus Gemcitabine were alive compared to 19 percent of patients receiving Gemcitabine plus placebo.
A statistically significant improvement in progression-free survival ( hazard ratio = 0.76; p = 0.006 ) also was demonstrated.
Although no difference in tumor response was observed ( 8.6 percent in patients receiving Tarceva plus Gemcitabine versus 7.9 percent in the Gemcitabine plus placebo arm ), the disease control rate ( complete response + partial response + stable disease ) was significantly improved ( 59 percent in patients receiving Tarceva plus Gemcitabine versus 49 percent in the Gemcitabine plus placebo arm, p = 0.036 ).
The global study was conducted by the National Cancer Institute of Canada in collaboration with OSI Pharmaceuticals.
Tarceva has a well-established safety profile.
In the Phase III study in pancreatic cancer, the most common adverse events reported were fatigue, rash, nausea, anorexia and diarrhea.
Rash was reported in 69 percent of patients who received Erlotinib plus Gemcitabine and in 30 percent of patients who received Gemcitabine plus placebo.
Diarrhea was reported in 48 percent of patients who received Erlotinib plus Gemcitabine and in 36 percent of patients who received Gemcitabine plus placebo.
Two percent of the patients discontinued Erlotinib because of rash and 2 percent because of diarrhea.
In addition, severe and potential fatal adverse events included interstitial lung disease-like complications, myocardial infarction or ischemia, cerebrovascular accident, and microangiopathic hemolytic anemia with thrombocytopenia.
Tarceva is a small molecule designed to target the human epidermal growth factor receptor 1 ( EGFR/HER1 ) pathway, which is one of the factors critical to cell growth in a number of different cancer types.
EGFR/HER1 is a component of the HER signaling pathway, which plays a role in the formation and growth of numerous cancers.
Tarceva is designed to inhibit the tyrosine kinase activity of the HER1 signaling pathway inside the cell, which may block tumor cell growth.
According to the World Health Organization, more than 216,000 people worldwide are diagnosed each year with pancreatic cancer.
The American Cancer Society predicts that in 2005 about 32,180 people in the United States will be diagnosed with pancreatic cancer and about 31,800 will die of the disease. Although pancreatic cancer accounts for 2 percent of new cancer cases in the United States, it is the fourth leading cause of all cancer deaths.
Most pancreatic tumors originate in the exocrine duct cells or in the cells that produce digestive enzymes ( acinar cells ). Called adenocarcinomas, these tumors account for nearly 95 percent of pancreatic cancers.
